NASDAQ · Medical - Devices
AVR (AVR) Stock
$8.28
+0.00%
NASDAQ: AVR
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Anteris Technologies Files Offering of Up to 5.39 Million Shares
MT Newswires · Jul 1, 2026
TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge
PR Newswire · Jun 15, 2026
France clearance marks key milestone for Anteris' pivotal PARADIGM Trial
Proactive · Jun 8, 2026
Anteris Technologies Global Receives French Regulator's Approval for DurAVR Trial in Aortic Stenosis
MT Newswires · Jun 8, 2026
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
GlobeNewswire · Jun 8, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held16.47%
Institutions Held66.90%
Institutions Float Held80.09%
Peer Comparison
About AVR
AVR is led by CEO Wayne Geoffrey Paterson, employs 136 people, headquartered in AU, publicly traded since 2024.
AVR stock trades at $8.28 with a market capitalization of $304.61M. The stock is valued at a price-to-earnings (P/E) ratio of -2.56, price-to-book of 0.87, price-to-sales of 203.52. Over the past 52 weeks the stock has ranged between $2.85 and $10.94, and currently trades 24.3% below its 52-week high.
On profitability, AVR generates a return on equity (ROE) of -124.40%, return on capital employed of -34.20%, an operating margin of -4700.00%, a net profit margin of -51.49%.